Avita, U.S. Department of Health and Human Services dermatology news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded Avita a five-year contract worth up to $53.9 million to support late-stage clinical development and procurement of ReCell Autologous Cell Harvesting Device to treat burns. The base contract commits $16.9 million to support U.S. development and PMA approval and to procure over 5,000 ReCell devices as an inventory in the case of mass casualty scenario involving burn injuries. The contract also includes options for up to an additional $37 million to support clinical trials potentially required by FDA as part of postmarket surveillance or as needed to expand the use of ReCell to the pediatric population. ...